Modifying PEST for Psoriatic Arthritis Screening

Last Update: Mar 24, 2025
A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ("ScreenX")
ClinicalTrials.gov Identifier:
NCT06382051
Novartis Reference Number:CAIN457ACA06
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada. Patients will be enrolled in the study for up to 66 days and will be asked to fill-out a PsA screening questionnaire at their first dermatologist visit. Patients screening positive for PsA will have a second visit with a rheumatologist where a full PsA diagnosis assessment will be performed. A remote 'end of study' (EOS) visit will be conducted by the dermatologist to document the patient's biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) treatment choice and status.

Condition
Plaque Psoriasis, Psoriatic Arthritis
Phase
Na
Overall Status
Recruiting
Number of Participants
502
Start Date
Jan 23, 2025
Completion Date
Apr 30, 2025
Gender
All
Age(s)
18 Years - (Adult, Older Adult)

Interventions

Diagnostic_test

PEST Screening group

PEST Screening group

Eligibility Criteria

Key inclusion criteria:

1. Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, as per provincial reimbursement criteria
2. Adult patients at the time of informed consent signature
3. Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
4. Residents of Canada

Key exclusion criteria:

1. Patients who have previously screened positive for PsA through PEST or any other screening method
2. Patients who have been diagnosed with PsA and/or followed by a rheumatologist
3. Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis)
4. Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition

Canada

Novartis Investigative Site

Recruiting

Hamilton,Ontario,L8n 1v6,Canada

Novartis Investigative Site

Recruiting

Stoney Creek,Ontario,L8g 1h1,Canada

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: +41613241111
Email: novartis.email@novartis.com

Novartis Pharmaceuticals

Phone: -
Email: -

Source URL: *https://prod1.novartis.com/clinicaltrials/study/nct06382051*

List of links present in page

1. https://clinicaltrials.gov/ct2/show/NCT06382051
2. #trial-eligibility
3. tel:+41613241111
4. mailto:novartis.email@novartis.com